NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA
- PMID: 8049205
- DOI: 10.1021/bi00197a003
NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA
Abstract
The hypothesis that the antitumor prodrug temozolomide is ring-opened to MTIC which then further breaks down to a reactive diazonium ion at guanine-rich sequences in DNA has been probed by NMR spectroscopy and computational techniques. Temozolomide is stable at acid pH but decomposes to MTIC at pH > 7; in contrast, MTIC is stable at alkaline pH values but rapidly fragments in a methylating mode at pH < 7. The proximate methylating agent is the reactive methyldiazonium species. Runs of guanine residues represent an accessible nucleophilic microenvironment in DNA site-specific conversion of the prodrug temozolomide to MTIC possibly via an activated water molecule in the major groove. Molecular modeling of the structure of temozolomide indicates that the prodrug can make a favorable noncovalent encounter with DNA. The known structure-activity relationships as well as the biological and clinical properties of temozolomide can be interpreted in terms of this model.
Similar articles
-
High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma.J Chromatogr B Biomed Sci Appl. 1997 Dec 5;703(1-2):225-33. doi: 10.1016/s0378-4347(97)00431-3. J Chromatogr B Biomed Sci Appl. 1997. PMID: 9448080
-
Antitumor imidazotetrazines. 25. Crystal structure of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (temozolomide) and structural comparisons with the related drugs mitozolomide and DTIC.J Med Chem. 1992 Sep 4;35(18):3377-82. doi: 10.1021/jm00096a013. J Med Chem. 1992. PMID: 1527789
-
Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide.Cancer Chemother Pharmacol. 1991;27(5):342-6. doi: 10.1007/BF00688855. Cancer Chemother Pharmacol. 1991. PMID: 1998993
-
New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance.Forum (Genova). 2000 Jul-Sep;10(3):274-85. Forum (Genova). 2000. PMID: 11007934 Review.
-
Triazene compounds: mechanism of action and related DNA repair systems.Pharmacol Res. 2007 Oct;56(4):275-87. doi: 10.1016/j.phrs.2007.08.003. Epub 2007 Aug 9. Pharmacol Res. 2007. PMID: 17897837 Review.
Cited by
-
Temozolomide-mediated DNA methylation in human myeloid precursor cells: differential involvement of intrinsic and extrinsic apoptotic pathways.Clin Cancer Res. 2013 May 15;19(10):2699-709. doi: 10.1158/1078-0432.CCR-12-2671. Epub 2013 Mar 27. Clin Cancer Res. 2013. PMID: 23536437 Free PMC article.
-
Comprehensive understanding of the adverse effects associated with temozolomide: a disproportionate analysis based on the FAERS database.Front Pharmacol. 2024 Aug 23;15:1437436. doi: 10.3389/fphar.2024.1437436. eCollection 2024. Front Pharmacol. 2024. PMID: 39246656 Free PMC article.
-
From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas.Cells. 2021 May 17;10(5):1225. doi: 10.3390/cells10051225. Cells. 2021. PMID: 34067729 Free PMC article. Review.
-
Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians.Int J Clin Oncol. 2007 Oct;12(5):341-9. doi: 10.1007/s10147-007-0687-5. Epub 2007 Oct 22. Int J Clin Oncol. 2007. PMID: 17929115
-
Temozolomide Efficacy and Metabolism: The Implicit Relevance of Nanoscale Delivery Systems.Molecules. 2022 May 30;27(11):3507. doi: 10.3390/molecules27113507. Molecules. 2022. PMID: 35684445 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources